M&A / Deals Pfizer signs licence agreement with Chai for AI drug discovery Pharmaceutical TechnologyPfizer and Chai Discovery have signed a licence deal enabling the former to incorporate Chai's AI platform into its drug discovery operations.Read full story pharminent June 5, 2026 (Last updated: June 5, 2026) Pharmaceutical Technology Pfizer and Chai Discovery have signed a licence deal enabling the former to incorporate Chai’s AI platform into its drug discovery operations. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Boan Biotech Submits BLA to FDA for Two Denosumab BiosimilarsNext: Biogen’s salanersen gains FDA breakthrough therapy designation for SMA Related Stories M&A / Deals Supernus and Indivior merge to create CNS mega-company with 11 approved drugs pharminent August 3, 2026 M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026
